Jamie McNab

Jamie McNab is an analyst at Slate Path Capital LP, a New York-based hedge fund known for its long/short equity investing approach and significant presence in alternative investments. In his current role, Jamie contributes to security selection and research across multiple asset classes, with a particular emphasis on equities—especially large-cap U.S. stocks and index-based options. He supports Slate Path’s flagship strategies, which often focus on sectors including pharmaceuticals and technology, as evident from the fund’s largest positions in companies like Teva Pharmaceutical Industries Ltd and ETF options on the NASDAQ 100 and S&P 500 indices.

Prior to joining Slate Path Capital, Jamie served as a research associate at Blue Ridge Capital, a distinguished long/short equity fund, where he gained deep expertise in fundamental analysis and investment research. His career thus reflects a strong pedigree in hedge fund research and portfolio analytics, working under influential managers and supporting funds known for rigorous, opportunistic investment strategies.

Jamie is based in New York, NY, and is recognized for his disciplined, research-driven approach to investing. Although explicit educational details are not listed in public sources, his career trajectory at top-tier hedge funds highlights specialized expertise in equity analysis, options, and multi-strategy portfolio management. He is regarded as a key contributor to Slate Path’s ability to generate alpha in challenging market environments, helping the fund outperform major indices over multiple periods.